ArticleFrontiers in pharmacology2025
Addition of bevacizumab to gefitinib plus chemotherapy as first-line therapy in EGFR L858R mutate advanced non-small cell lung cancer patients.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: For advanced non-small cell lung cancer patients with the epidermal growth factor receptor L858R mutation, the efficacy of the combination of tyrosine kinase inhibitor (TKI) and chemotherapy is suboptimal. Currently, it is unclear whether the combination of bevacizumab, gefitinib, and chemotherapy could improve the survival. Materials and methods: Data was retrospectively collected at Shandong Provincial Hospital between June 2019 and December 2022. The patients were divided into two groups, ATC group receiving bevacizumab, gefitinib, and chemotherapy, and TC group receiving gefitinib and chemotherapy. After propensity score matching (PSM), progression-free survival (PFS) and overall survival (OS) were calculated along with the objective response rate (ORR) and disease control rate (DCR). Results: The study enrolled 217 patients, 58 in the ATC group and 149 in the TC group, and was adjusted to 55 and 118 after PSM, respectively. Both the ORR and DCR were higher in the ATC group compared to the TC group (ORR: 76.4% versus 65.3%; DCR: 89.1% versus 80.1%). After 41.30 months of follow-up, the first-line PFS in the ATC group was significantly longer than in the TC group, while OS was not (PFS: 22.26 months versus 19.18 months, P = 0.02; OS: 42.18 months versus 39.42 months, P = 0.91). Univariate and multivariate analyses indicated that ATC treatment and the absence of brain metastases positively predict PFS, with no variables that dependently predict OS. Conclusion: The combination of bevacizumab, gefitinib, and chemotherapy significantly benefits patients with the L858R mutation in first-line PFS but not OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.